The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Construction of a Multi-center Database for Primary IgA Nephropathy
1 other identifier
observational
2,000
1 country
1
Brief Summary
- 1.Establish an IgAN cohort collaboration group and expert committee to carry out registration research.
- 2.Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis.
- 3.Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation.
- 4.Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
April 19, 2021
CompletedFirst Posted
Study publicly available on registry
April 26, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedMay 28, 2024
May 1, 2024
3.6 years
April 19, 2021
May 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
The proportion of a decline in estimated glomerular filtration rate by > 50% from baseline
To evaluate the renal function
1 year
The proportion of doubling serum creatinine compared with baseline
To evaluate the renal function
1 year
Incidence of ESRD
To evaluate the renal function
1 year
Secondary Outcomes (2)
Incidence of cardiovascular events
1 year
Incidence of All-cause death
1 year
Eligibility Criteria
Biopsy-proven primary IgAN patients
You may qualify if:
- No age limit, no gender limit;
- Kidney biopsy confirmed primary IgA nephropathy;
- Sign the informed consent form voluntarily
You may not qualify if:
- IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;
- IgAN is clinically diagnosed but not confirmed by pathology;
- The patient refuses to participate;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruijin Hospitallead
- RenJi Hospitalcollaborator
- Huashan Hospitalcollaborator
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universitycollaborator
Study Sites (1)
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jingyuan Xie
Ruijin Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 19, 2021
First Posted
April 26, 2021
Study Start
December 1, 2020
Primary Completion
June 30, 2024
Study Completion
June 30, 2024
Last Updated
May 28, 2024
Record last verified: 2024-05